Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2014 May 27

PMID 24860833

Citations 70

Authors

Su-Xia Han

E Bai

Gui-Hua Jin

Chen-Chen He

Xi-Jing Guo

Li-Juan Wang

Meng Li

Xia Ying

Qing Zhu

Affiliations

Soon will be listed here.

Abstract

Purpose: Yes-associated protein (YAP) and PDZ-binding motif (TAZ) are two important effectors of Hippo pathway controlling the balance of organ size and carcinogenesis. Amphiregulin (AREG) is a member of the epidermal growth factor family, a direct target gene of YAP and TAZ. The role of these proteins in hepatocellular carcinoma (HCC) is unclear.

Methods: The expression of YAP, TAZ, and AREG in HCC was analyzed by immunohistochemical staining. The level of secreted serum AREG was also assayed by enzyme-linked immunosorbent (ELISA) assay.

Results: YAP, TAZ, and AREG were expressed in 69.2% (27/39), 66.7% (26/39), and 61.5% (24/39) of HCC patients. The expression of YAP was significantly correlated with Edmondson stage (P>0.05), serum AFP level (P>0.05), and HCC prognosis (P>0.05). AREG expression was also significantly correlated with Edmondson stage (P>0.05) and serum AFP level (P>0.05). In addition, the expression of serum AREG was higher than serum AFP in HCC patients. Further multivariate analysis showed that YAP expression was an independent prognostic factor that significantly affected the overall survival of HCC patients.

Conclusions: YAP maybe an independent prognostic indicator for HCC patients and serum AREG may be a serological biomarker of HCC.

Citing Articles

Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression.

Lee N, Choi M, Lee E, Koo J Arch Pharm Res. 2024; 47(6):558-570.

PMID: 38874747 PMC: 11217110. DOI: 10.1007/s12272-024-01501-5.

Signaling pathways in liver cancer: pathogenesis and targeted therapy.

Xue Y, Ruan Y, Wang Y, Xiao P, Xu J Mol Biomed. 2024; 5(1):20.

PMID: 38816668 PMC: 11139849. DOI: 10.1186/s43556-024-00184-0.

Unveiling the cancer risk nexus of the steatotic liver.

Kim J, Seki E Trends Endocrinol Metab. 2024; 35(8):708-719.

PMID: 38531699 PMC: 11321945. DOI: 10.1016/j.tem.2024.02.017.

TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.

Shu B, Zhou Y, Lei G, Peng Y, Ding C, Li Z Cancer Sci. 2024; 115(5):1476-1491.

PMID: 38475938 PMC: 11093211. DOI: 10.1111/cas.16134.

Effects of RNA methylation on Tumor angiogenesis and cancer progression.

Han M, Sun H, Zhou Q, Liu J, Hu J, Yuan W Mol Cancer. 2023; 22(1):198.

PMID: 38053093 PMC: 10698974. DOI: 10.1186/s12943-023-01879-8.

References

Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y . Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 2011; 71(6):2162-71. PMC: 3070402. DOI: 10.1158/0008-5472.CAN-10-3268. View

Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba I . HER family receptor and ligand status in thymic carcinoma. Lung Cancer. 2012; 77(3):515-21. DOI: 10.1016/j.lungcan.2012.05.108. View

Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M . Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474(7350):179-83. DOI: 10.1038/nature10137. View

Overholtzer M, Zhang J, Smolen G, Muir B, Li W, Sgroi D . Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006; 103(33):12405-10. PMC: 1533802. DOI: 10.1073/pnas.0605579103. View

Bhat K, Salazar K, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F . The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011; 25(24):2594-609. PMC: 3248681. DOI: 10.1101/gad.176800.111. View

Steinhardt A, Gayyed M, Klein A, Dong J, Maitra A, Pan D . Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008; 39(11):1582-9. PMC: 2720436. DOI: 10.1016/j.humpath.2008.04.012. View

Zhang J, Ji J, Yu M, Overholtzer M, Smolen G, Wang R . YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009; 11(12):1444-50. PMC: 2819909. DOI: 10.1038/ncb1993. View

Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J . Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther. 2013; 14(6):511-20. PMC: 3813567. DOI: 10.4161/cbt.24345. View

Zender L, Spector M, Xue W, Flemming P, Cordon-Cardo C, Silke J . Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125(7):1253-67. PMC: 3026384. DOI: 10.1016/j.cell.2006.05.030. View

10.

Berasain C, Castillo J, Perugorria M, Prieto J, Avila M . Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett. 2007; 254(1):30-41. DOI: 10.1016/j.canlet.2007.01.015. View

11.

Lee K, Lee J, Kim T, Kim T, Park H, Byun J . The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107(18):8248-53. PMC: 2889558. DOI: 10.1073/pnas.0912203107. View

12.

Lam-Himlin D, Daniels J, Gayyed M, Dong J, Maitra A, Pan D . The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer. 2008; 37(4):103-9. DOI: 10.1007/s12029-007-0010-8. View

13.

Chan S, Lim C, Guo K, Peng Ng C, Lee I, Hunziker W . A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68(8):2592-8. DOI: 10.1158/0008-5472.CAN-07-2696. View

14.

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View

15.

Xu C, Liu C, Huang W, Tu S, Wan F . Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro. Acta Biochim Biophys Sin (Shanghai). 2013; 45(4):268-79. DOI: 10.1093/abbs/gmt006. View

16.

Liu A, Poon R, Luk J . MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010; 394(3):623-7. DOI: 10.1016/j.bbrc.2010.03.036. View

17.

Yang N, Morrison C, Liu P, Miecznikowski J, Bshara W, Han S . TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle. 2012; 11(15):2922-30. PMC: 3419062. DOI: 10.4161/cc.21386. View

18.

Zhang T, Zhang J, You X, Liu Q, DU Y, Gao Y . Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012; 56(6):2051-9. DOI: 10.1002/hep.25899. View

19.

Jie L, Fan W, Weiqi D, Yingqun Z, Ling X, Miao S . The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013; 2013:187070. PMC: 3748736. DOI: 10.1155/2013/187070. View

20.

Zhou Z, Hao Y, Liu N, Raptis L, Tsao M, Yang X . TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011; 30(18):2181-6. DOI: 10.1038/onc.2010.606. View